Aeovian Pharmaceuticals: Valuation, Funding & Investors
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules that restore cellular metabolic quality control by inhibiting mTORC1 or CD38. The company’s lead candidate, AV078, is a first-in-class CNS-penetrant selective mTORC1 inhibitor in Phase 2 development for refractory epilepsy associated with tuberous sclerosis complex (TSC), a rare genetic disorder driven by hyperactive mTORC1 signaling. Aeovian is developing a pipeline of highly selective inhibitors with the potential to address multiple rare and age-related diseases.
Leadership & Board
- Current Number of Employees
- 13
- Current LinkedIn Followers
- 1,993
Latest Estimated Valuation
- Total Amount Raised
- $55M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $55M
- Latest Funding Round
- Series B
Employee Trend
Aeovian Pharmaceuticals had 13 employees as of November 2, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Aeovian Pharmaceuticals had 1,993 followers as of November 2, 2026. The number of followers increased by 1 (0.05%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 16, 2025 | Series B | $55.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Symbiosis | Series B |
| Foresite Capital | Series B |
| Sofinnova Investments | Series B |
| Luma Group | Series B |
| Apollo Health Ventures | Series B |
| CTI Life Sciences Fund | Series B |
| TSC Alliance Endowment Fund | Series B |
| Wilson Sonsini | Series B |
Similar Companies
A snapshot of private companies similar to Aeovian Pharmaceuticals, helping you discover and navigate related company profiles.
Related News and Analysis
